Mucopolysaccharidosis I - 101 Studies Found
Active, not recruiting |
: Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I : Mucopolysaccharidosis I : 2015-02-19 : Drug: AGT-181 (HIRMAb-IDUA) intravenous infusion over 3-4 hours |
Enrolling by invitation |
: Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I : : 2024-05-13 |
Active, not recruiting |
: Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I : Mucopolysaccharidosis I : 2017-02-09 : Drug: AGT-181 Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion |
Recruiting |
: Mucopolysaccharidosis I (MPS I) Registry : Mucopolysaccharidosis I (MPS I) : 2005-09-02 |
Completed |
: Immune Tolerance Study With Aldurazyme® (Laronidase) : Mucopolysaccharidosis I : 2008-08-13 :
|
Enrolling by invitation |
: Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in MPS I :
: 2014-09-03 : Drug: Intrathecal recombinant human alpha iduronidase Intrathecal recombinant human alpha iduronidase ev |
Completed |
: Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease :
: 2017-05-11 :
|
Recruiting |
: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I : MPS I : 2016-02-29 : Biological: SB-318 A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, |
Completed |
: Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients :
|